WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC/DDDs and alterations from the 2 April 2020 meeting
Published Thursday May 7 2020

Lists of new ATC codes, DDDs and alterations decided at the latest meeting of the WHO International Working Group for Drug Statistics Methodology 2 April 2020 (postponed from 19 March 2020) are now published on the website (Lists of new ATC/DDDs and alterations). Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology before 1 September 2020. If no objections are received before this date, the new ATC codes, DDDs and alterations will be considered final and included in the January 2021 issue of the ATC/DDD Index.

Please note ATC codes alterations  as a consequence of new ATC 3rd and 4th levels to be implemented in the ATC Index 2021: J05AJ Integrase inhibitors, L01CE Topoisomerase 1 inhibitors, L01E Protein kinase inhibitors with 4th levels, and 4th levels in L01X Other antineoplastic agents, see list of new ATC level codes (other than 5th levels) here, (second table).

Archive

07.05.20
07.05.20
23.03.20
23.03.20
04.12.19
02.12.19
29.11.19
29.11.19
12.11.19
02.05.19
02.05.19
18.12.18
13.12.18
26.11.18
21.11.18
17.10.18
15.05.18
15.05.18
23.02.18
22.12.17
29.11.17
28.11.17
09.05.17
09.05.17
21.02.17
15.12.16
05.12.16
02.11.16
19.05.16
22.01.16
18.12.15
09.12.15
09.12.15
08.12.15
02.12.15
28.10.15
05.05.15
30.04.15
16.12.14

Last updated: 2020-05-07